Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Jabbour E, et al. Among authors: thomas da. Cancer. 2017 Jan 1;123(2):294-302. doi: 10.1002/cncr.30264. Epub 2016 Sep 7. Cancer. 2017. PMID: 27602508 Free PMC article.
Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.
Faderl S, Thomas DA, O'Brien S, Ravandi F, Garcia-Manero G, Borthakur G, Ferrajoli A, Verstovsek S, Ayoubi M, Rytting M, Feliu J, Kantarjian HM. Faderl S, et al. Among authors: thomas da. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):54-9. doi: 10.3816/CLML.2011.n.007. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21454191 Clinical Trial.
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. Tsimberidou AM, et al. Among authors: thomas da. Cancer. 2003 Apr 1;97(7):1711-20. doi: 10.1002/cncr.11238. Cancer. 2003. PMID: 12655528 Free article.
Rituximab in relapsed or refractory hairy cell leukemia.
Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, Cortes J, Kantarjian HM. Thomas DA, et al. Blood. 2003 Dec 1;102(12):3906-11. doi: 10.1182/blood-2003-02-0630. Epub 2003 Jun 19. Blood. 2003. PMID: 12816862 Free article. Clinical Trial.
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ. Ferrajoli A, et al. Among authors: thomas da. Cancer. 2003 Aug 15;98(4):773-8. doi: 10.1002/cncr.11551. Cancer. 2003. PMID: 12910522 Free article. Clinical Trial.
376 results